Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Rochester, MN
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Durham, NC
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  6/1/2016
mi
from
South Brisbane,
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 6/1/2016
mi
from
South Brisbane,
Click here to add this to my saved trials
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Status: Enrolling
Updated:  6/9/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
Status: Enrolling
Updated: 6/9/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients
A Pilot Randomized Trial of the Comprehensive Transitional Care Program for Medically Underserved Colorectal Cancer Surgery Patients
Status: Enrolling
Updated:  6/13/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients
A Pilot Randomized Trial of the Comprehensive Transitional Care Program for Medically Underserved Colorectal Cancer Surgery Patients
Status: Enrolling
Updated: 6/13/2016
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Virtual Colonoscopy (VC) for Primary Colorectal Screening
CT Virtual Colonoscopy for Primary Colorectal Screening
Status: Enrolling
Updated:  6/14/2016
University of Wisconsin
mi
from
Madison, WI
Virtual Colonoscopy (VC) for Primary Colorectal Screening
CT Virtual Colonoscopy for Primary Colorectal Screening
Status: Enrolling
Updated: 6/14/2016
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer
Status: Enrolling
Updated:  6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Trial of Second Generation Designer T Cells in Colorectal Carcinoma
Phase II/Pilot Trial of Second Generation Designer T Cells in Colorectal Cancer
Status: Enrolling
Updated: 6/16/2016
Roger Williams Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.
Status: Enrolling
Updated:  6/28/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.
Status: Enrolling
Updated: 6/28/2016
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.
Status: Enrolling
Updated:  6/28/2016
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer
Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) With Erlotinib in Patients With Advanced Biliary Tract Cancer.
Status: Enrolling
Updated: 6/28/2016
Vanderbilt-Ingram Cancer Center - Cool Springs
mi
from
Nashville, TN
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Tunnell Cancer Center at Beebe Medical Center
mi
from
Lewes, DE
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
CCOP - Christiana Care Health Services
mi
from
Newark, DE
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
University Medical Center of Southern Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
CCOP - Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated:  6/28/2016
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer
Phase II Trial of LE SN38 in Patients With Metastatic Colorectal Cancer After Progression on Oxaliplatin
Status: Enrolling
Updated: 6/28/2016
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
Status: Enrolling
Updated:  6/30/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers
Status: Enrolling
Updated: 6/30/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated:  7/11/2016
Georgetown University Medical Center, Gastroenterology
mi
from
Washington,
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated: 7/11/2016
Georgetown University Medical Center, Gastroenterology
mi
from
Washington,
Click here to add this to my saved trials
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated:  7/11/2016
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated: 7/11/2016
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated:  7/11/2016
Univeristy of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Effect of Anesthesia on Force Application During Colonoscopy
Effect of Anesthesia on Force Application During Colonoscopy
Status: Enrolling
Updated: 7/11/2016
Univeristy of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
John Stoddard Cancer Center at Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Mercy Cancer Center at Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Midlands Cancer Center at Midlands Community Hospital
mi
from
Papillion, NE
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Midlands Cancer Center at Midlands Community Hospital
mi
from
Papillion, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
MBCCOP - University of New Mexico HSC
mi
from
Albuquerque, NM
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
MBCCOP - University of New Mexico HSC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Penn State Cancer Institute at Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
CCOP - St. Vincent Hospital Cancer Center, Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated:  7/12/2016
Westmead Hospital
mi
from
Westmead,
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER
Status: Enrolling
Updated: 7/12/2016
Westmead Hospital
mi
from
Westmead,
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Howard University Cancer Center
mi
from
Washington,
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Howard University Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated:  7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy
Status: Enrolling
Updated: 7/12/2016
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials